Treatment with any other investigational agent within weeks (or within five half-lives of the investigational product, whichever is shorter) prior to cycle , day (minimum of week between prior therapy and study enrollment); patients must be >= weeks since any investigational agent administered as part of a phase study (also referred to as an early phase I study or pre-phase I study where a sub-therapeutic dose of drug is administered) at the coordinating center PIs discretion, and should have recovered to eligibility levels from any toxicities Participants who are currently receiving any other investigational agents; treatment with an investigational agent within weeks prior to planned initiation of study therapy is allowed provided that any drug-related toxicity has completely resolved Treatment with another investigational agent under the following conditions: Concomitant treatment with another investigational agent while participating this trial. Treatment with an investigational agent within weeks of the first dose of treatment SAFETY RUN-IN: Patients participating in another trial of an investigational agent within weeks of the first dose of the study Known or suspected allergy to the investigational agent or any agent given in association with this trial. Other investigational agent(s) within days prior starting to study treatment. Exposure to any other investigational agent at any time within weeks before the first dose of study treatment Treatment with any investigational agent within weeks prior to baseline Prior participant in another protocol using an investigational agent within half-lives of the investigational agent Participants is taking another investigational agent Plans to initiate treatment with an investigational agent during the study Have taken an investigational agent within days of visit Use of any standard chemotherapy or other investigational agent(s) within week of study enrollment Patients receiving investigational agent within days of enrollment. However, the principal investigator (PI) may approve prior use of an investigational agent if the agent is not expected to interfere with the safety or the efficacy of alpha--antitrypsin. Treatment with any investigational agent within days of first administration of study treatment is not permitted Patient is currently using, or planning to use another investigational agent Patients who have been treated with an investigational agent within days prior to the first dose of study drug. Use of an investigational agent within weeks of enrollment (day ) Use of other investigational agent for prostate cancer Known or suspected allergy to the investigational agent or any agent given in association with this trial Subjects who anticipate use of other investigational or non-investigational agents for the treatment of MDS during the study period, aside from a stable dose of erythropoietin stimulating agent started > weeks prior to screening for this study. Treatment with any investigational agent within days of first administration of study treatment. Administration of any investigational agent within weeks prior to initiating study treatment Cytotoxic therapy or investigational agent use within days Patients participating in another trial of an investigational agent within weeks of the st dose of the study Treatment with a prior investigational agent within days of first dose of investigational medication Subject has received an investigational therapeutic agent for prostate cancer within weeks prior to the administration of I-MIP- Any previous treatment with a DDR agent, including any of the investigational agents An interval of >= weeks after the last administration of any investigational agent or any other treatment prior to first dose of pembrolizumab Administration of any investigational agent within weeks prior to initiating study treatment Concurrent treatment with any other investigational agent Is currently participating in a study of an investigational agent and received an investigational agent within weeks of the first dose of treatment Treatment with other investigational agent(s) within days of planned lymphodepletion Treatment with any other investigational agent within weeks prior to the first dose of MEDI and tremelimumab Any investigational agent within weeks prior to initiating study treatment Any investigational agent within weeks prior to initiating study treatment Any investigational agent within weeks of study treatment initiation Patients may not receive concurrent treatment with other investigational or commercial agent(s) for treatment of their breast cancer Use of any investigational agent within weeks prior to study entry. Patients receiving any other standard or investigational treatment for their cancer, or any other investigational agent for any indication, within the past weeks prior to initiation of treatment with study drugs Treatment with an investigational anti-cancer agent within weeks prior to enrollment into the study Patients receiving any other standard or investigational treatment for their cancer, or any other investigational agent for any indication, within the past weeks prior to initiation of treatment with study drugs Research participant must be at least weeks out from having received the last dose of investigational agent Use of any investigational agent within weeks prior to the Baseline Visit. Patients should not have received an investigational agent for at least weeks prior to the first study drug dose The use of any investigational agent in the month before enrollment into the study Investigational agent within weeks of first dose of study treatment Patients may not have used any investigational agent within weeks prior to enrollment into the study While on this study, patients may not be treated with any other investigational agent for any purpose until relapse or progression Known history of hepatitis B or C as these patients may be at risk of disease reactivation when treated with the chemotherapy and/or the investigational agent Investigational agent: >= days must have elapsed from treatment with a different investigational agent Administration of any unlicensed or investigational agent within weeks of entry to the study No prior investigational agent in the weeks prior to initiation of therapy Use of investigational agent within days of signing informed consent Use of any investigational agent within days of the first radiation dose Use of investigational agent within last days Use of any investigational agent within weeks prior to study entry. Use of an investigational agent within weeks of enrollment Treatment with any other investigational agent within days prior to enrolment. weeks from any investigational agent Exposure to any investigational agent within weeks prior to initiation of study treatment. Less than weeks since use of another investigational agent Treatment with any investigational agent within weeks prior to baseline Treatment with any investigational agent within weeks prior baseline Patients who have received treatment with any other investigational agent within weeks before initiation of study treatment Any antineoplastic agent for the primary malignancy (standard or investigational) without delayed toxicity within weeks prior to first administration of IMP and during study with exceptions Treatment with any other investigational anti-leukemia agent Any investigational agent(s) within weeks prior to entry Concurrent administration of any other investigational agent considered to have potential efficacy in the treatment of breast cancer Any investigational agent within weeks prior to initiating study treatment TREATMENT: Patients who have had prior treatment with any of the other investigational agents or combinations on this protocol are eligible but will not receive the same investigational agent (everolimus or trametinib) or combination (AZD/combination or veliparib/temozolomide); instead, patients will receive an investigational agent or combination prospectively identified to work on a different target in their tumors mutation/aberrant pathway Concurrent treatment with an investigational agent Subjects having received any other investigational agents within weeks prior to the\n first study drug administration and have not recovered completely (to AEs < Grade )\n from the side effects of the earlier investigational agent Patients with a history of prior therapy with another investigational agent within weeks of the first planned dose of PF- Concurrent treatment with an investigational agent other than the investigational agent(s) used in this study OR treatment within weeks of study entry with any investigational agent(s) or device(s) Any intravesicular or other chemotherapy treatment within weeks or any investigational agent within weeks prior to the initial dose of study drug. ? days elapsed from the administration of any investigational agent Use of any investigational agent within the weeks preceding enrollment Any investigational agent within weeks of Day of trial drug treatment First day of dosing with tesevatinib is less than weeks from treatment with another investigational agent No investigational agent within weeks prior to first dose of study drug. Have been treated with an investigational agent within weeks prior to the first day of IP administration. Administration of any investigational agent within days of first dose of study drug Any investigational agent within the previous days. Treatment with radiotherapy, any chemotherapeutic agent, systemic steroids used as an anti-neoplastic agent, or any other investigational anti-cancer agent within weeks prior to Cycle , Day Treatment with any other investigational agent Previously received treatment with RGX- or another investigational agent that is a known LXR agonist. Treatment with an investigational agent within weeks of starting treatment. Use of an investigational agent or an investigational device within days before administration of first dose of NKTR-. Use of investigational agents within weeks prior to study enrollment (within weeks if the treatment was with a long-acting agent such as a monoclonal antibody). Administration of any investigational agent within days of first dose of study drug Treatment with any investigational agent within three weeks prior to first dose in this study Treatment with any investigational agent within days of first administration of study treatment Treatment with any investigational agent within three weeks prior to first dose in this study Taking an investigational agent within weeks of initiation of everolimus Received any chemotherapeutic or targeted agent (approved or investigational) for NSCLC within weeks of initiation of pacritinib (with the exception of erlotinib) Known or suspected allergy to the investigational agent or any agent given in association with this trial At least weeks must have elapsed from the use of any other investigational agent prior to starting study drug Subjects who received an investigational agent < days prior to their first day of study drug administration. In addition, the first dose of AG- should not occur before a period ? half-lives of the investigational agent has elapsed. Use of an investigational agent within weeks of enrollment (day visit) Use of any investigational agent within weeks prior to study entry. Subjects who received a small molecule investigational agent < days prior to their first day of study drug administration. In addition, the first dose of AG- should not occur before a period ? half-lives of the investigational agent has elapsed. Patients who have participated in a window study (treatment with an investigational agent prior to surgery for =< weeks) are eligible; patients must have discontinued the investigational agent at least days before participation Treatment with an investigational agent within weeks before dosing Treatment with any investigational agent within days of first administration of study treatment Use of an investigational agent, including an investigational anti-cancer agent, within days prior to the first dose of study drug No use of an investigational agent within weeks of starting ECP Current active treatment with an investigational agent complete abstinence from intercourse from weeks prior to administration of the st dose of study agent and months after the last dose of study agent; or Any investigational agent within weeks of first dose of study treatment Treatment with a an investigational agent within days prior to the first dose of dasatinib/ATRA or planning to receive an investigational agent during the study An investigational agent within the past days Current use of an investigational agent Any investigational agent, other than NEOD, within weeks Use of an investigational therapeutic agent with weeks of enrollment Treatment with an investigational agent within days prior to the first dose of SNX? or planning to receive an investigational agent during the study. Use of an investigational agent within weeks of Day visit. Other investigational agent within weeks prior to initiation of study therapy Use of any investigational agent within days prior to Baseline. Concurrent treatment or treatment within weeks of study entry with any other investigational agent or chemotherapy. Concurrent treatment or treatment within weeks of study entry with any other investigational agent or chemotherapy. Patients receiving any other standard or investigational treatment for their cancer, or any other investigational agent for any indication, within the past weeks prior to initiation of treatment with study drugs Known or suspected allergy to the investigational agent or any agent given in association with this trial. Treatment with any investigational agent within weeks prior to first dose in this study. Treatment with another investigational agent under the following conditions: Concomitant treatment with another investigational agent while participating in this trial. Current treatment with another investigational agent. Use of any other investigational agent within days before day . More than weeks from any investigational agent. Use of any investigational agent within the last days Treatment with an unapproved, investigational agent within days of the first dose of study drug Concurrent treatment with an investigational agent Treatment with any investigational agent <= weeks prior to first dose of study treatment Received an investigational agent < days prior to their first day of study drug administration. In addition, the first dose of AG- should not occur before a period ? half-lives of the investigational agent has elapsed Use of an investigational therapeutic agent within days Subject may not receive another investigational agent. Must be days from the administration of any investigational agent or prior cytotoxic therapy with the following exceptions: Use of an investigational agent within the past days Use of any investigational agent within days prior to start of CA- Patients may not have received an investigational agent within weeks of starting this trial Donor must not be currently enrolled on another investigational agent study. Received treatment with an investigational agent within weeks of study entry, or is actively participating in another interventional clinical study. Any other investigational agent within days of study entry Any antineoplastic agent (standard or investigational) within weeks prior to starting trial treatment Received an antineoplastic therapy or investigational agent after treatment with talazoparib in the originating protocol. days from the administration of any investigational agent Systemic therapy or investigational agent administered < days prior to treatment with nintedanib Prior treatment with an agent targeting the exportin Subjects who have received treatment with an investigational agent within days of the projected first administration of Investigational Product (Day ) Use of investigational agent within days of study entry Patient is using or plans to use an investigational agent for the prevention or treatment of VOD. Concurrent treatment with other investigational agent Has received an investigational study agent within the previous days, or is currently participating in or scheduled to participate in any other clinical study with an investigational agent during the -week study period Exposure to any investigational agent (defined as any agent not approved by the Food and Drug Administration [FDA]) within days prior to the Screening Visit Planned treatment with agent targeting PIK/mTOR pathway (either standard of care or investigational agent) Subjects must not receive concurrent or prior use of an immunosuppressive agent within days of the first dose of investigational agent, with the following exceptions and notes: Subjects must not have received another investigational agent within the shorter of weeks or half-lives before the first dose of investigational agent. use of any investigational drug within weeks of dosing (unless a longer time period is required by local regulations or the investigational agent) Use of an investigational agent within weeks of enrollment No investigational agent within weeks prior to first dose of study drug